Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients
Articolo
Data di Pubblicazione:
2019
Citazione:
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients / Tovoli, Francesco; Ielasi, Luca; Casadei Gardini, Andrea; Granito, Alessandro; Foschi, Francesco Giuseppe; Rovesti, Giulia; Negrini, Giulia; Orsi, Giulia; Renzulli, Matteo; Piscaglia, Fabio. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 71:6(2019), pp. 1175-1183. [10.1016/j.jhep.2019.08.015]
Abstract:
Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interruption. The impact of the physicians experience on the management of these AEs and the relative implications on clinical outcomes are unknown. We verified if the AEs management changed over time and if these modifications impacted on treatment duration and overall survival (OS).
Tipologia CRIS:
Articolo su rivista
Keywords:
adverse events; hepatocellular carcinoma; learning curve; outcome; prognosis; sorafenib
Elenco autori:
Tovoli, Francesco; Ielasi, Luca; Casadei Gardini, Andrea; Granito, Alessandro; Foschi, Francesco Giuseppe; Rovesti, Giulia; Negrini, Giulia; Orsi, Giulia; Renzulli, Matteo; Piscaglia, Fabio
Link alla scheda completa:
Link al Full Text:
Pubblicato in: